Spyre Therapeutics (SYRE) Projected to Post Earnings on Thursday

Spyre Therapeutics (NASDAQ:SYRE) is projected to release its earnings data before the market opens on Thursday, March 6th. Analysts expect Spyre Therapeutics to post earnings of ($0.89) per share and revenue of $2.10 million for the quarter.

Spyre Therapeutics Trading Down 8.0 %

NASDAQ:SYRE opened at $19.00 on Thursday. The firm has a 50-day moving average price of $22.54 and a two-hundred day moving average price of $26.89. Spyre Therapeutics has a twelve month low of $18.81 and a twelve month high of $47.97. The company has a market capitalization of $977.19 million, a P/E ratio of -2.54 and a beta of 2.85.

Analyst Ratings Changes

SYRE has been the subject of several recent research reports. Wedbush restated an “outperform” rating and set a $65.00 target price on shares of Spyre Therapeutics in a report on Monday, January 13th. The Goldman Sachs Group upgraded shares of Spyre Therapeutics to a “strong-buy” rating in a report on Tuesday, February 18th. Finally, Robert W. Baird raised their target price on shares of Spyre Therapeutics from $50.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Spyre Therapeutics currently has an average rating of “Buy” and a consensus target price of $54.83.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).